MSP-2020 explained
MSP-2020 is a psychedelic drug of the tryptamine and pyrrolidinylmethylindole families related to psilocybin which is under development for the treatment of mental disorders such as major depressive disorder.[1] [2] [3] It is taken orally. The drug acts as a serotonin 5-HT2A receptor agonist and is described as a prodrug.[4] It is a 3-pyrrolidine–indole derivative and hence cyclized tryptamine and is said to be psilocybin-like but with stronger effects and a shorter duration.[5] MSP-2020 was originated by Mindset Pharma and is now under development by Otsuka America Pharmaceutical, which acquired Mindset Pharma in January 2024.[6] As of January 2026, MSP-2020 is in phase 1 clinical trials for major depressive disorder. MSP-2020 was patented by Mindset Pharma in 2021, though its specific chemical structure has not been disclosed and is unclear.[7] [8]
See also
Notes and References
- Web site: MSP 2020 . 14 January 2026 . AdisInsight . 15 January 2026 . MSP 2020 is an oral pyrrolidine-indole derivative psilocybin like high potency, short acting drug being developed by Otsuka America [...] .
- Web site: Delving into the Latest Updates on MSP-2020 with Synapse . 12 January 2026 . Synapse . 15 January 2026 .
- Web site: MSP-2020 Drug Profile . Ozmosi . 15 January 2026 .
- Web site: Pharma M . Mindset Pharma Inc. Scientific Summary February 2021 . February 2021 . In Vitro Profile of Selected Mindset Prodrug Candidates .
- Pharma M . Mindset Pharma Selects Lead Clinical Candidates From "Family 2" of its Next Generation Psychedelic Drug Portfolio . 5 October 2022 . GlobeNewswire News Room . 15 January 2026 . MSP-2020 and MSP-2003, exhibiting a stronger and shorter acting psychedelic effect than psilocybin in preclinical testing, are selected for IND enabling studies [...] (“Mindset” or the “Company”), a drug discovery company developing novel, optimized, next-generation psychedelic and non-psychedelic medications to treat neuropsychiatric and neurological disorders with unmet medical needs, today announced that after extensive preclinical screening studies, a lead psychedelic drug clinical candidate, MSP-2020, and a second back-up drug candidate, MSP-2003, have been selected from its Family 2 program in collaboration with The McQuade Center for Strategic Research and Development, LLC (MSRD), a member of the global Otsuka family of pharmaceutical companies, to advance to IND enabling studies. [...] MSP-2020 and MSP-2003 are both novel and patentable compounds. They are covered under Mindset’s United States Patent and Trademark Office (USPTO) patent number 17/387,864, titled “3-Pyrrolidine-Indole Derivatives as Serotonergic Psychedelic Agents for the Treatment of CNS Disorders.” Mindset has received a notice of allowance from the USPTO for this application. [...] In side-by-side comparisons to psilocybin and psilocin, the two drug candidates elicit in vitro and behavioral responses consistent with a stronger and shorter acting psychedelic effect than psilocybin and a significantly reduced half-life. The drug candidates are CNS penetrant and exhibit high oral bioavailability in different species. .
- Web site: Otsuka makes psychedelics play, buying Mindset . pharmaphorum . September 2023 . 15 January 2026 . To date, Otsuka has been working with Mindset on the company's second family of psilocybin-based drug candidates led by MSP-2020 and back-up compound MSP-2003, which offer "greater potency than LSD combined with a shorter psychedelic effect than psilocybin." .
- Sabnis RW . Novel 3-Pyrrolidineindole Derivatives as Serotonergic Psychedelic Agents for Treating Psychosis and Mental Illnesses Such as Depression and Post-Traumatic Stress Disorder . ACS Medicinal Chemistry Letters . 16 . 1 . 18–19 . January 2025 . 39811142 . 11726355 . 10.1021/acsmedchemlett.4c00581 .
- Web site: 3-pyrrolidine-indole derivatives as serotonergic psychedelic agents for the treatment of cns disorders . 4 February 2021 . Google Patents . 15 January 2026 .
